Tumori最新文献

{"title":"Knowledge and resources gaps for adolescent and young adult (AYA) cancer patients: Results from survAYA, an Italian National Survey.","authors":"Alberto Puccini, Sara Farinatti, Alexia Francesca Bertuzzi, Giacomo Giulio Baldi, Alice Indini, Paola Quarello, Elena Pagani Bagliacca, Maurizio Mascarin, Marco Maruzzo, Matteo Lambertini, Lorena Incorvaia, Giuseppe Maria Milano, Giulia Zucchetti, Assunta Tornesello, Marco Spinelli, Elisabetta Razzaboni, Teresa Perillo, Laura Marziali, Andrea Ferrari, Fedro Alessandro Peccatori, Angela Toss","doi":"10.1177/03008916261452431","DOIUrl":"10.1177/03008916261452431","url":null,"abstract":"<p><strong>Purpose: </strong>Adolescents and young adults (AYA; 15-39 years) represent a distinct oncology population with specific biological and psychosocial needs. Despite growing awareness, AYA patients often face fragmented care between pediatric and adult settings, resulting in diagnostic delays, limited clinical trial access, and inadequate psychosocial support. In 2021, the AIOM-AIEOP AYA Working Group was established in Italy to promote awareness and address these challenges.</p><p><strong>Methods: </strong>An anonymous, voluntary online survey was designed by the AIOM-AIEOP AYA Working Group and distributed during the AIOM National Congress (November 2024). Using iPads at a dedicated booth, oncologists and other healthcare professionals completed a questionnaire exploring knowledge, perceptions, and access to AYA-focused services. Data were analyzed using descriptive statistics.</p><p><strong>Results: </strong>Ninety-seven professionals participated (median age 34 years; 75% female; 56% medical oncologists). Although 86% reported access to genetic counseling and 84% to fertility preservation services, only 18% had AYA-dedicated spaces and 21% employed trained AYA-specific staff. Forty-four percent felt competent in assessing hereditary cancer syndromes, and fewer than 25% were aware of AYA-focused research or trials. Psychological support was commonly available, whereas educational coaching and peer support groups were rare (5% each). Lifestyle counseling was frequent, but structured survivorship care and long-term follow-up were limited.</p><p><strong>Conclusions: </strong>This survey reveals substantial gaps in AYA oncology services in Italy, particularly regarding dedicated staff, infrastructure, and training. National coordination and implementation of standardized frameworks, such as through the AIOM-AIEOP network, are essential to ensure equitable, comprehensive care for AYA patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261452431"},"PeriodicalIF":2.0,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148536970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.","authors":"Rashad Ismayilov, Buge Oz, Arzu Oguz, Ozden Altundag","doi":"10.1177/03008916261458950","DOIUrl":"https://doi.org/10.1177/03008916261458950","url":null,"abstract":"<p><strong>Background: </strong>Synovial sarcoma (SS) is molecularly defined by the pathognomonic <i>SS18::SSX</i> fusion, a master epigenetic driver. While <i>NTRK</i> gene fusions are high-priority tissue-agnostic targets for TRK inhibitors like larotrectinib, their co-occurrence with established lineage-defining drivers in sarcomas is exceptionally rare and presents a therapeutic paradox.</p><p><strong>Case presentation: </strong>A 78-year-old female was diagnosed with metastatic biphasic SS. Molecular profiling via targeted RNA sequencing identified a pathogenic <i>PDE3A-NTRK2</i> fusion (Tier 1A) alongside the canonical <i>SS18</i> rearrangement. Despite the presence of this usually actionable target, second-line treatment with larotrectinib resulted in rapid clinical deterioration and \"explosive\" tumor growth, signifying absolute primary resistance to TRK inhibition. The disease followed an aggressive course typical of chemorefractory SS, leading to the patient's death ten months after initial diagnosis.</p><p><strong>Conclusion: </strong>This case provides critical clinical evidence of the \"driver versus passenger\" phenomenon in precision oncology. It demonstrates that the epigenetic dominance of the <i>SS18::SSX</i> fusion can override the therapeutic relevance of a concurrent <i>NTRK</i> fusion. Our findings serve as a cautionary note: actionable targets detected via next-generation sequencing must be interpreted within the tumor's canonical biological context, as lineage-defining translocations may render secondary kinase alterations therapeutically inert.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261458950"},"PeriodicalIF":2.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148353818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.","authors":"Andrea Remo, Maria Grazia Tibiletti, Giovan Battista Rossi, Ileana Carnevali, Cristina Oliani","doi":"10.1177/03008916261451688","DOIUrl":"https://doi.org/10.1177/03008916261451688","url":null,"abstract":"<p><p>Hereditary cancer genetics is increasingly recognized as an integral component of cancer care, contributing to treatment, early detection, and risk reduction strategies for patients and their relatives. In this context, several hereditary cancer programs, databases, recommendations, and guidelines have been implemented within the Italian National Health System and at hospital level. However, independent and specific quality indicators for hereditary tumor management are still lacking, limiting the ability to evaluate activities across individual centers. To address this gap, AIFET (Associazione Italiana Familiarità ed Ereditarietà Tumori) has established a dedicated scientific committee for the development of such quality indicators. Here, for the first time to our knowledge, we present a set of 37 quality indicators derived from a national Italian survey. The indicators were organised into four sections: General indicators (applicable to all syndromes), specific to hereditary breast and ovarian cancer, specific to colorectal cancer and polyposis, specific to melanoma predisposition. By promoting consistency across centres, this model may not only enhance the quality of care nationally but also foster collaboration with European institutions toward shared standards in hereditary cancer management.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261451688"},"PeriodicalIF":2.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148353793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.","authors":"Valter Giantin, Chiara Curreri, Caterina Ugolini, Chiara De Toni, Silvia Stragliotto, Sara Marin, Lavinia Patetta, Marco Maruzzo, Alessandra Feltrin, Sara Lonardi, Antonella Brunello, Vittorina Zagonel","doi":"10.1177/03008916261437928","DOIUrl":"10.1177/03008916261437928","url":null,"abstract":"<p><strong>Background: </strong>Issues related to end-of-life decisions (ELDs) generate impassioned debates in society. Our study aimed at investigating attitudes in care of cancer patients at the end-of-life (EOL); ascertaining the opinion of healthcare professionals (HCPs), patients, and caregivers.</p><p><strong>Methods: </strong>An anonymous and self-administered questionnaire was delivered to HCPs (physicians, nurses, psychologists, and social workers), patients and family caregivers at Veneto Institute of Oncology, Italy, and 425 questionnaires were collected (136 HCPs, 171 patients, 118 caregivers).</p><p><strong>Results: </strong>Withholding life-sustaining treatment (LST) was declared by 11.3% of physicians and nurses and withdrawing by 19.4%, whereas 46.8% declared starting LST, and 48.4% did not discontinue LST. Most HCPs (75.7%) were in favor of patient's right to anticipate EOL, and 86.4% of withholding/withdrawing LST upon patient's request, with 62.4% HCPs agreeing on lethal drug doses to be allowed upon request of the patient. The majority (80.1%) disagreed that \"<i>life is an unavailable asset and there is no right to die</i>\". For patients and caregivers, in ELDs greater value was given to self-determination first, with family members and trustees' subsequent involvement. A considerable number of HCPs reported feeling inadequate to communicate bad news.</p><p><strong>Conclusion: </strong>Despite the limitations imposed by the cross-sectional nature, this study adds information with regard to EOL in oncology setting in Italy. Our study shows that an attitude to prolonging patient's life in ELDs is still prevalent among HCPs in an Italian oncological setting, although there are signs of change. Communicating bad news emerges as an issue, along with HCPs' awareness that they need more education and training.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261437928"},"PeriodicalIF":2.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148353808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.","authors":"Giovanni Leuzzi, Pamela Minicozzi, Paolo Verderio, Giuseppe Lo Russo, Claudia Proto, Chiara Maura Ciniselli, Michele Ferrari, Alessandro Pardolesi, Arsela Prelaj, Teresa Beninato, Matteo Calderoni, Clarissa Uslenghi, Piergiorgio Solli","doi":"10.1177/03008916261454505","DOIUrl":"https://doi.org/10.1177/03008916261454505","url":null,"abstract":"<p><p>For decades, the surgical management of non-small cell lung cancer (NSCLC) has been predominantly guided by anatomical staging. However, this traditional approach often overlooks the \"fourth dimension\" of cancer biology: time. This narrative review explores how circadian and circannual rhythms act as silent drivers of oncological prognosis, deeply influencing the interaction between host immunity and tumor behavior. Evidence suggests that the integrity of the molecular clock, regulated by genes such as TIMELESS and RORA, is not merely a biochemical detail but a critical determinant of survival and metastatic potential. Furthermore, environmental cues like Vitamin D synthesis and photoperiodism introduce seasonal fluctuations in patient resilience, creating specific \"windows of vulnerability\" during surgical stress. Moving toward a \"time-aware\" oncology opens the possibility of synchronizing clinical interventions-from the hour/season of surgery to immunotherapy scheduling-with the patient's biological rhythms. Such an approach represents a promising, cost-effective frontier to further personalize the therapeutic journey and optimize long-term outcomes in resectable NSCLC.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261454505"},"PeriodicalIF":2.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148353803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.","authors":"Catia Angiolini, Antonella Ferro, Luca Moscetti","doi":"10.1177/03008916261460701","DOIUrl":"https://doi.org/10.1177/03008916261460701","url":null,"abstract":"<p><p>The follow up in early breast cancer represented a major challenging in oncology practice. Current guidelines are supported by evidence demonstrating no benefit of intensive surveillance.Despite evidence, many oncologists still practice a more intensive follow-up, prompting studies to evaluate and improve real-world effectiveness: the effectiveness of routine screening is further questioned by the varied relapse patterns across breast cancer subtypes. Rethinking surveillance as a calibrated clinical choice, rather than an automatic procedure, is a scientific and civic duty in the era of personalized and sustainable healthcare.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261460701"},"PeriodicalIF":2.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148353776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.","authors":"Andrea Vingiani, Alberta Piccolo, Adele Busico, Iolanda Capone, Elena Tamborini, Federica Perrone, Cinzia De Marco, Paolo Verderio, Chiara M Ciniselli, Claudia Proto, Marta Brambilla, Giuseppe Lo Russo, Elena Conca, Andrea Devecchi, Daniele Lorenzini, Luca Agnelli, Giancarlo Pruneri","doi":"10.1177/03008916261438383","DOIUrl":"10.1177/03008916261438383","url":null,"abstract":"<p><strong>Purpose: </strong>Liquid biopsy has emerged as a valuable tool for detecting therapeutic targets and resistance mechanisms. This study evaluated the analytical performance and clinical utility of TruSight Oncology 500 ctDNA (TSO500) compared to the FDA-approved Guardant360 CDx (G360) in detecting actionable alterations in non-small cell lung cancer (NSCLC) patients progressing on targeted therapies.</p><p><strong>Patients and methods: </strong>We analyzed 44 plasma samples from 36 consecutive metastatic NSCLC patients with known molecular drivers (<i>EGFR</i> and <i>BRAF</i> mutations, <i>ALK</i> and <i>RET</i> fusions) progressing on targeted therapy. The comparative analysis included 31 paired samples from 27 patients. Valid results were obtained from G360 in 42/44 cases (95.45%) and TSO500 in 32/44 samples (72.8%).</p><p><strong>Results: </strong>TSO500 demonstrated high sensitivity for G360-identified variants (81.02% overall; 85.26% for pathogenic/likely pathogenic variants). Concordance was particularly high for ESCAT I alterations (95.2% sensitivity), including 100% sensitivity for gene fusions (five detected fusions). TSO500 identified 102 additional variants not detected by G360. Among nine patients with concurrent tissue biopsy, TSO500 detected 16 potentially actionable mutations absent in tissue samples. Both assays identified resistance mutations in 12/26 patients (46.2%), with TSO500 detecting all but three G360-identified alterations. High correlation was observed between variant allele frequencies (Pearson's r = 0.89).</p><p><strong>Conclusions: </strong>TSO500 demonstrates high concordance with G360 for detecting actionable alterations and robust fusion identification. Its ability to detect additional variants and resistance mutations not found in tissue highlights its potential value in guiding personalized treatment decisions for NSCLC patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261438383"},"PeriodicalIF":2.0,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148309704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-of-life care: A retrospective study comparing sarcoma and patients with carcinoma.","authors":"Luca Zambelli, Giacomo Massa, Francesca Ricchini, Ernesto Zecca, Salvatore Provenzano, Gabriele Tinè, Rosalba Miceli, Augusto Caraceni, Paolo Giovanni Casali","doi":"10.1177/03008916261446214","DOIUrl":"10.1177/03008916261446214","url":null,"abstract":"<p><strong>Background: </strong>Soft tissue and bone sarcomas may carry a considerable symptom burden, which typically worsens in the final weeks of life. To help clarify personalized palliative care needs, we investigated discrepancies in end-of-life management between patients with sarcoma and those with the most common carcinomas.</p><p><strong>Patients and methods: </strong>This retrospective cohort study enrolled all sarcoma patients who died between 1 January 2018 - 31 October 2023, either in the palliative care unit or in medical oncology units, at a large cancer hospital in northern Italy. Each patient with sarcoma was matched with up to three randomly selected patients with carcinoma. Matching was based on age, year of death and unit. Electronic health records were reviewed.</p><p><strong>Results: </strong>Thirty-six patients with sarcoma were matched with 96 patients with carcinoma (44 lung cancer, 40 breast cancer and 12 colorectal cancer). Patients with sarcoma had a significantly higher chance of palliative sedation compared with patients with carcinoma (OR=32.5). The most common refractory symptom in patients with sarcoma was dyspnea (50%), followed by pain (26%). The average opioid dose difference between patient groups during sedation was as high as 220 mg. The final recorded Richmond Agitation-Sedation Scale score (RASS) was on average -4.4 for patients with sarcoma who died in hospice compared to -2.5 for those who died in an oncology unit.</p><p><strong>Conclusions: </strong>In our series, patients with sarcoma had a substantially higher risk of experiencing refractory symptoms requiring palliative sedation compared to patients with the most common cancers. Pain and dyspnea were the most common refractory symptoms in patients with sarcoma, resulting in higher dosages of opioids and possibly impacting sedation deepness. This study suggests that patients with sarcoma may pose special challenges to end-of-life care.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261446214"},"PeriodicalIF":2.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148259699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A practical framework of preoperative imaging for non-small cell lung cancer: Thoracic surgeons' expectations from radiologists.","authors":"Ulas Kumbasar, Gamze Durhan","doi":"10.1177/03008916261447808","DOIUrl":"https://doi.org/10.1177/03008916261447808","url":null,"abstract":"<p><p>Accurate preoperative imaging is essential for determining operability, guiding surgical planning, and optimizing outcomes in the treatment of non-small cell lung cancer (NSCLC). This paper outlines thoracic surgeons' expectations from radiologists in the preoperative evaluation of NSCLC, aiming to enhance multidisciplinary collaboration and improve radiologic reporting standards. A narrative review of imaging modalities-including CT, PET-CT, and MRI-was conducted to identify key radiologic parameters relevant to surgical decision-making. The paper integrates current Tumor, nodes, metastasis (TNM) staging criteria, tumor morphology, anatomical localization, and invasion patterns, with practical surgical implications. Radiologists are expected to provide precise measurements of tumor size and morphology, assess nodal involvement and metastatic spread, and identify critical anatomical relationships and variations. Imaging should detail tumor invasion into adjacent structures such as the chest wall, mediastinum, and vascular or airway components. The paper also emphasizes the importance of imaging in evaluating suitability for minimally invasive surgery, guiding lesion localization, and assessing underlying lung pathology and post-induction therapy response. A standardized, surgeon-oriented imaging report enhances surgical planning, reduces intraoperative risks, and supports personalized treatment strategies. This paper serves as a practical guide for radiologists to align imaging assessments with thoracic surgical needs, ultimately improving patient outcomes.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261447808"},"PeriodicalIF":3.1,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study.","authors":"Michela Palleschi, Filippo Merloni, Andrea Prochowski Iamurri, Emanuela Scarpi, Danila Diano, Caterina Gianni, Domenico Barone, Giandomenico Di Menna, Chiara Casadei, Roberta Maltoni, Ugo De Giorgi, Antonino Musolino, Alice Rossi","doi":"10.1177/03008916261447104","DOIUrl":"10.1177/03008916261447104","url":null,"abstract":"<p><p>Multiparametric Whole-Body Magnetic Resonance Imaging (WB-MRI) may enhance bone metastasis detection in metastatic breast cancer (mBC) patients. We report preliminary results from a prospective clinical trial investigating WB-MRI utility in BC patients with bone-predominant lesions, equivocal imaging findings or oligometastatic disease (OMD). Fifty-nine consecutive patients underwent baseline staging with standard imaging techniques (SIT), followed by WB-MRI. WB-MRI led to treatment-plan modifications in 40% of cases; 83% of lobular carcinoma cases exhibited additional metastases on WB-MRI. Among the 23 patients who underwent at least one reassessment by WB-MRI and SIT, the concordance rate was 69.6%. Among 18 OMD patients, WB-MRI led to the redefinition of the disease status in 44.4% of cases. These findings underscore the value of WB-MRI in BC.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261447104"},"PeriodicalIF":2.0,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}